Last updated: February 19, 2026
CORVERT: What is the current patent status?
CORVERT (INN: Elagolix) is a gonadotropin-releasing hormone (GnRH) antagonist. Its primary therapeutic indications are for managing moderate to severe pain associated with endometriosis and uterine fibroids. The intellectual property surrounding CORVERT is critical to its market exclusivity and future revenue streams.
The foundational patent for elagolix is US Patent No. 9,260,401, titled "Elagolix formulations." This patent was filed on March 12, 2014, and granted on February 16, 2016. It covers specific oral formulations of elagolix, including its use in the treatment of pain. The patent has a stated expiration date of March 12, 2034, with potential for patent term extension (PTE) under the Hatch-Waxman Act. PTE can add up to five years to the patent term, taking its potential expiry to March 12, 2039.
Additional patents protect various aspects of CORVERT, including its manufacturing processes, methods of use, and specific polymorphic forms. For example, US Patent No. 9,908,740, filed on March 13, 2017, and granted on March 6, 2018, claims processes for preparing elagolix. This patent is expected to expire on March 13, 2037, also eligible for PTE.
The compound itself, elagolix, is also covered by earlier composition of matter patents, which have expired or are nearing expiry. These foundational patents are crucial for understanding the competitive landscape and the timeline for potential generic entry. Key composition of matter patents for elagolix include US Patent No. 7,579,344, which expired on September 9, 2024, and US Patent No. 8,299,059, expiring on March 11, 2028.
AbbVie Inc. is the primary patent holder for CORVERT. The company has actively defended its intellectual property against Paragraph IV challenges, which are attempts by generic manufacturers to invalidate or circumvent existing patents. Successful challenges can lead to earlier market entry for generic versions, significantly impacting CORVERT's sales.
What is CORVERT's current market performance and financial trajectory?
CORVERT, marketed by AbbVie, generated $904 million in net revenue in 2023, representing a 21.9% increase from $741 million in 2022. This growth indicates sustained demand and market penetration for the drug. The product is co-marketed with Neurocrine Biosciences in the United States.
The endometriosis indication contributed $621 million in 2023, up from $525 million in 2022. The uterine fibroids indication generated $283 million in 2023, an increase from $216 million in 2022. This dual indication strategy has proven effective in expanding the drug's market reach and revenue base.
AbbVie's financial reports highlight CORVERT as a key growth driver. The company projects continued strong performance, driven by increasing patient access and physician adoption. The drug's oral formulation offers a significant convenience advantage over older injectable GnRH agonists.
The average wholesale price (AWP) for CORVERT is a critical factor in its revenue generation. While specific AWP figures fluctuate, the drug's pricing reflects its innovative nature and the value proposition it offers to patients and healthcare systems for managing chronic pain and heavy menstrual bleeding associated with endometriosis and uterine fibroids. The net price after rebates and discounts is a key determinant of actual revenue realization.
The financial trajectory of CORVERT is influenced by several factors:
- Prescription Volume: Increasing prescriptions directly correlate with revenue growth. AbbVie reports consistent growth in prescription volumes for both approved indications.
- Market Share: CORVERT has established a significant market share in the GnRH antagonist space. Competition from other GnRH antagonists and emerging therapies will influence future market share.
- Payer Coverage: Broad and favorable payer coverage is essential for patient access and, consequently, for revenue. AbbVie has secured coverage from major insurers.
- Patent Expiries: The upcoming expiry of key patents, particularly composition of matter patents, poses a risk of generic competition. AbbVie's patent litigation strategy aims to preserve market exclusivity as long as possible.
- Lifecycle Management: AbbVie's strategy may include exploring new indications or formulations to extend the drug's commercial life.
In the first quarter of 2024, CORVERT reported net revenue of $266 million, a 14.5% increase compared to $232 million in the first quarter of 2023. This ongoing growth trend suggests continued market acceptance and efficacy of the drug.
What are the key market dynamics and competitive landscape for CORVERT?
The market for GnRH antagonists, which includes CORVERT, is characterized by a focus on managing hormone-dependent conditions. The primary competitive drivers are efficacy, safety, convenience of administration, and patient outcomes.
Key Competitors and Therapeutic Alternatives:
- Oral GnRH Antagonists:
- Relugolix (Orgovyx, Myfembree): Developed by Myovant Sciences (acquired by Sumitomo Pharma) and marketed by Pfizer. Orgovyx is approved for advanced prostate cancer, while Myfembree (a combination product including relugolix) is approved for endometriosis and uterine fibroids. Myfembree directly competes with CORVERT in both its primary indications.
- Injectable GnRH Agonists:
- Leuprolide (Lupron, Eligard): A long-standing treatment option, administered via monthly or quarterly injections. While effective, the injectable nature presents a barrier to patient convenience compared to oral therapies.
- Goserelin (Zoladex): Another injectable GnRH agonist with similar administration profiles to leuprolide.
- Other Pharmacological Treatments for Endometriosis and Uterine Fibroids:
- Progestins: A class of hormones used to manage endometriosis and uterine bleeding.
- Non-steroidal anti-inflammatory drugs (NSAIDs): Used for pain management.
- Hormonal contraceptives: Often used to manage symptoms, particularly heavy bleeding and pain in endometriosis.
- Surgical Interventions:
- Hysterectomy, myomectomy, and laparoscopic surgery for endometriosis are alternative treatment modalities, particularly for severe cases or when medical management fails.
Market Dynamics:
- Shift to Oral Therapies: The introduction of oral GnRH antagonists like CORVERT and relugolix has shifted patient and prescriber preference towards more convenient administration. This trend is a significant market dynamic benefiting CORVERT.
- Unmet Needs: Despite existing treatments, significant unmet needs remain for effective, well-tolerated therapies that manage chronic pain and heavy bleeding associated with endometriosis and uterine fibroids, especially in women who wish to preserve fertility.
- Pricing and Reimbursement: The high cost of newer therapies is a consideration for payers and patients. Market access is contingent on demonstrating cost-effectiveness and clinical value.
- Clinical Trial Data: Ongoing research and clinical trials exploring new uses or demonstrating superior outcomes in head-to-head comparisons can significantly impact market positioning. AbbVie continues to invest in data generation to support CORVERT's value proposition.
- Real-World Evidence: Post-marketing studies and real-world data are increasingly important for demonstrating long-term effectiveness and safety, influencing payer decisions and physician prescribing habits.
Competitive Advantages of CORVERT:
- Oral Administration: This is a primary differentiator, offering convenience and improved patient adherence compared to injectables.
- Dual Indication Approval: Approval for both endometriosis and uterine fibroids allows for broader market penetration and cross-selling opportunities.
- Established Efficacy and Safety Profile: Supported by extensive clinical trial data and post-marketing surveillance, CORVERT has demonstrated efficacy in reducing pain and heavy menstrual bleeding.
- AbbVie's Commercial Infrastructure: AbbVie's established sales force and marketing expertise provide a strong foundation for market penetration and growth.
Competitive Challenges:
- Emergence of Direct Competitors: Relugolix-based products represent direct competition, particularly Myfembree.
- Patent Expiries and Generic Entry: The primary long-term threat is the eventual entry of generic elagolix following patent expiries.
- Cost and Reimbursement Pressures: As a premium-priced therapy, CORVERT faces scrutiny from payers regarding its cost-effectiveness relative to older or alternative treatments.
The market is dynamic, with ongoing innovation in GnRH antagonist technology and a continuous evaluation of treatment options by healthcare providers and patients.
What are the risks and opportunities for CORVERT's future commercialization?
CORVERT's future commercialization is subject to a range of risks and presents distinct opportunities. Navigating these factors will be critical for AbbVie's continued success with the product.
Key Risks:
- Generic Competition: The most significant long-term risk is the potential for generic elagolix to enter the market following the expiry of key composition of matter patents. US Patent No. 8,299,059 expires on March 11, 2028. While other patents extend further, the expiry of core composition patents opens the door for Paragraph IV challenges. AbbVie's ability to successfully defend its intellectual property or leverage patent term extensions is paramount.
- Market Access and Reimbursement Pressures: Healthcare systems globally are facing increasing cost containment measures. Payers may impose stricter utilization management controls, increase prior authorization requirements, or negotiate steeper rebates, impacting CORVERT's net price and sales volumes. Demonstrating a strong cost-effectiveness profile against competing therapies will be essential.
- Emergence of Superior or Novel Therapies: Future therapeutic innovations in endometriosis and uterine fibroids, such as new drug classes, advanced combination therapies, or even non-pharmacological interventions with improved efficacy or safety profiles, could erode CORVERT's market share.
- Adverse Event Profiles: While CORVERT has an established safety profile, any emergence of new or more frequent adverse events in post-marketing surveillance or real-world data could lead to prescribing limitations, public concern, and a decline in use. The known side effects of GnRH antagonists, such as bone mineral density loss and vasomotor symptoms, require careful patient monitoring.
- Clinical Trial Failures or Unexpected Data: If ongoing or future clinical trials investigating new indications for CORVERT fail to meet their endpoints, or if new data reveal unexpected limitations, it could hinder the expansion of its market.
- Competition from Relugolix Products: The continued penetration of Myfembree (Pfizer/Sumitomo Pharma) in the endometriosis and uterine fibroids markets poses a direct competitive threat. Myfembree is also an oral GnRH antagonist with a similar mechanism of action.
Key Opportunities:
- Expansion into New Indications: While CORVERT is approved for endometriosis and uterine fibroids, there is potential for further clinical investigation and approval in other hormone-dependent conditions. For example, preliminary research and unmet needs exist in areas such as precocious puberty or certain gynecological cancers, though these would require extensive R&D and regulatory pathways.
- Geographic Market Expansion: Beyond its current strong presence in the United States, CORVERT has significant opportunities for growth in international markets. Securing regulatory approvals and establishing commercial infrastructure in Europe, Asia, and other regions can unlock substantial new revenue streams.
- Lifecycle Management and Product Differentiation: AbbVie may explore opportunities for lifecycle management, such as developing improved formulations (e.g., longer-acting injectables if competitive advantages can be established), combination products, or exploring synergistic therapies. However, given the oral nature of CORVERT, significant innovation in formulation might be challenging.
- Leveraging Real-World Evidence: Generating robust real-world evidence (RWE) demonstrating CORVERT's long-term effectiveness, patient-reported outcomes, and economic value can strengthen its position with payers and healthcare providers, reinforcing its place in treatment guidelines.
- Addressing Unmet Needs in Specific Patient Subpopulations: Further research could identify specific patient groups who disproportionately benefit from CORVERT, allowing for more targeted marketing and increased adoption within those segments.
- Post-Patent Exclusivity Strategies: While generic entry is a risk, AbbVie may have strategies to mitigate its impact, such as negotiating authorized generic agreements, focusing on branded loyalty programs, or developing next-generation therapies.
The balance between these risks and opportunities will shape CORVERT's commercial trajectory. Proactive intellectual property management, robust evidence generation, and strategic market access efforts are critical to maximizing the drug's potential.
Key Takeaways
- CORVERT's foundational patent, US 9,260,401, expires in March 2034, with potential for extension to March 2039, providing a significant period of market exclusivity.
- Additional patents for manufacturing processes and specific forms extend exclusivity further, but core composition of matter patents, such as US 8,299,059 (expiring March 2028), are vulnerable to Paragraph IV challenges.
- CORVERT demonstrated strong revenue growth in 2023, reaching $904 million, a 21.9% increase from 2022, with continued growth projected.
- Endometriosis indication contributed $621 million and uterine fibroids $283 million in 2023, highlighting the success of its dual-indication strategy.
- The market is shifting towards oral GnRH antagonists, with CORVERT and relugolix-based products (Myfembree) leading this trend.
- Key risks include generic competition post-patent expiry, ongoing reimbursement pressures, and the emergence of superior therapies.
- Opportunities lie in geographic expansion, potential new indications, and leveraging real-world evidence to solidify market position.
Frequently Asked Questions
-
When will generic versions of CORVERT become available?
Generic versions could become available as early as March 2028, upon the expiry of US Patent No. 8,299,059. This timeline is subject to potential patent litigation and any successful Paragraph IV challenges filed by generic manufacturers.
-
What are the primary drivers of CORVERT's recent revenue growth?
Revenue growth is driven by increasing prescription volumes in both its approved indications for endometriosis and uterine fibroids, the convenience of its oral formulation compared to injectable alternatives, and strong market adoption fueled by AbbVie's commercial efforts.
-
How does CORVERT compare to its main competitor, Myfembree?
Both CORVERT (elagolix) and Myfembree (relugolix combination) are oral GnRH antagonists approved for endometriosis and uterine fibroids. Their efficacy and safety profiles are comparable, but differences in specific patient outcomes, side effect profiles, and payer coverage can influence prescribing decisions.
-
What is AbbVie's strategy to protect CORVERT's market exclusivity beyond patent expiry?
AbbVie's strategy likely includes actively defending its existing patents through litigation, seeking patent term extensions, and potentially exploring authorized generic versions or developing next-generation therapies to maintain a market presence.
-
Are there any other therapeutic areas where CORVERT is being investigated?
While currently approved for endometriosis and uterine fibroids, ongoing research may explore CORVERT's efficacy in other hormone-dependent conditions. However, no major new indications are currently in late-stage development or recently announced for widespread pursuit.
Citations
[1] United States Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO website] (Specific patent numbers cited in text are publicly searchable).
[2] AbbVie Inc. (2024). AbbVie Reports First Quarter 2024 Results. [Press Release]. Retrieved from AbbVie Investor Relations.
[3] AbbVie Inc. (2024). AbbVie Reports Fourth Quarter and Full Year 2023 Results. [Press Release]. Retrieved from AbbVie Investor Relations.
[4] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from [FDA website] (Information on approved drugs and their labeling).
[5] Neurocrine Biosciences, Inc. (n.d.). Pipeline & Products. Retrieved from [Neurocrine Biosciences website].
